Biotech Startups

2 investors

2 investors

ZYMEDI is a drug discovery company that partners through R&D joint ventures, strategic investments, and in-licensing arrangements. It works with collaborators across the pharmaceutical and biotechnology sector.

2 investors

WSG describes itself as an investment or holding company focused on growth in the life sciences and microelectronics fields, with stated interest in the semiconductor, AI infrastructure, and biotechnology sectors. The page addresses shareholders and describes the company's strategy of scaling businesses in these high-growth areas.

2 investors

MicrobiotiX develops bacteriophage-based therapeutics targeting multi-drug resistant bacterial infections, including WHO/CDC priority pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and E. coli. The company operates a phage discovery and development platform with a library of about 1,000 bacteriophages, in-silico modules, and GMP production facilities, and its lead pipeline MP101 has entered clinical trials with first-patient-in completed.

2 investors

Based on the partner page listing major Korean hospitals, pharmaceutical firms, and international biotech institutions, the company appears to operate in healthcare or biotech, but the page does not explicitly state the company's core business or customer focus.

2 investors

Surginex develops lipid nanoparticle and RNA platforms for therapeutic applications, serving pharmaceutical and biotech companies in drug development.

2 investors

CDMOgen (씨드모젠) is a contract development and manufacturing organization specializing in viral vector- and mRNA-based gene therapies and vaccines, offering CDO, CMO, and CRO services including GMP manufacturing and quality/analytical testing. It serves biopharmaceutical developers and was the first in South Korea to receive GMP manufacturing approval for gene therapy products.

2 investors

APITbio develops antibody-based therapeutics using a proprietary fully human antibody library, with platforms for antibody discovery, engineering, optimization, production, and bispecific antibody creation. Its pipeline includes monoclonal antibodies, bispecific antibodies, and a CAR-T program under joint research.

2 investors

TXINNO is a biotech company developing small-molecule innovative anticancer drugs, with a scientific focus on the innate immune system and RAS signaling pathways. Its work spans drug discovery platforms and a therapeutic pipeline aimed at treating cancer patients.

2 investors

AccuRna develops drug delivery systems for nucleic acid therapeutics, including antisense oligonucleotides, siRNA, miRNA, and mRNA-based treatments. The company focuses on enabling the development of novel medicines for refractory diseases with no current cure.

2 investors

Ac-Planta develops and manufactures biostimulant products that enhance plants' tolerance to drought, high temperature, and salt stress, along with agricultural and horticultural materials for farms and plant factories. The company applies epigenetics and acetic acid-based biotechnology to address food security and environmental challenges caused by climate change.

2 investors

IMMUNOSENS manufactures in vitro diagnostic pharmaceuticals and third-class medical devices for clinical diagnostic purposes. The company holds regulatory approvals from Japanese authorities for these medical products.

2 investors

Orizuru Therapeutics develops cellular therapy products and regenerative medicine treatments utilizing iPS cell-related technology. The company supports drug discovery research and establishes regenerative medicine research infrastructure for the Japanese healthcare and biotechnology sectors.

2 investors

Cuorips develops regenerative medicine products based on human iPS cell technology, including its heart muscle cell sheet "Heart®" (Rehart) for treating severe heart failure caused by ischemic cardiomyopathy, along with catheter-based therapies and compound drugs (YS series). The Japan-based company, spun out of Osaka University research, also builds cell mass-manufacturing infrastructure (VMaCS) and is listed on the Tokyo Stock Exchange Growth market.

2 investors

Solasia is a pharmaceutical company that in-licenses promising drug candidates from overseas and domestic pharma and biotech companies and develops them through clinical trials for the Japanese and Asian markets. Founded in 2006, it focuses on supplying cancer-related medicines to patients across Japan and other Asian countries.

2 investors

Tokiwa Bio develops the Stealth-type RNA vector (SRV™), a non-integrating gene delivery vector that can introduce multiple or large genes into cells at high efficiency for gene therapy. The company also applies SRV™ to cell reprogramming for regenerative medicine and to biopharmaceutical manufacturing.

2 investors

Hynts Technology develops nanotechnology-based products for cellular delivery and extraction applications. The company offers nanostructured membrane stamps, microscope-mounted stamping systems, and cell processing services for research and biotech applications.

2 investors

FIMECS, Inc. is a Japanese drug discovery company researching and developing new pharmaceuticals based on targeted protein degradation mechanisms.

2 investors

BrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.

2 investors

PtBio develops genome editing technology and bio-DX tools for analyzing the genomes of industrially used organisms, positioning itself as a platform provider. Its applications include allergy-free eggs, CO2-converting microalgae for carbon recycling, advanced medical treatments, resource-recycling agriculture, aquatic resource supply, and bio-manufacturing.

2 investors

A company with expertise in developing pharmaceutical products through clinical trial phases (IND to NDA/BLA) and launching them for patients in Japan and Asia.

2 investors

HoloBio is a Japanese molecular biology research company that studies the unique functions of region-specific plants, animals, and symbiotic microorganisms across Japan. It aims to discover and apply these biological functions to develop new technologies, while also supporting senior researchers in launching ventures.

2 investors

United Immunity develops a myeloid-targeting platform using pullulan-based nanoparticles to selectively deliver therapeutic agents and vaccine antigens to macrophages and dendritic cells. The platform targets these immune cells through DC-SIGN receptor binding for cancer immunotherapy, vaccines, and treatment of fibrosis, viral infections, and inflammatory diseases.

2 investors